A study of 696 patients with NSCLC who received pembrolizumab as first-line treatment revealed that the co- mutation of TP53 and KRAS G12C was associated with the longest PFS and OS, surpassing outcomes associated with single mutation or wild-type status (38). This evidence concerns the gene KRAS and non-small cell lung carcinoma.